ABIONYX Pharma Bilan de santé

Santé financière contrôle des critères 6/6

ABIONYX Pharma possède un total de capitaux propres de €9.4M et une dette totale de €1.4M, ce qui porte son ratio d'endettement à 14.4%. Son actif total et son passif total sont €15.5M et de €6.0M.

Informations clés

14.4%

Ratio d'endettement

€1.36m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	€5.30m
Fonds propres	€9.45m
Total du passif	€6.01m
Total des actifs	€15.46m

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 609 ( €7.5M ) dépassent ses passifs à court terme ( €3.3M ).

Passif à long terme: Les actifs à court terme de 609 ( €7.5M ) dépassent ses passifs à long terme ( €2.7M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 609 dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de 609 a été réduit de 14.8% à 14.4% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: 609 dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: 609 devrait disposer d'une marge de trésorerie suffisante pour 7 mois sur la base des estimations de flux de trésorerie disponible, mais a depuis levé des capitaux supplémentaires.

ABIONYX Pharma Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

ABIONYX Pharma RACERS Study Clinical Results in Brain-Fog Selected for Poster Presentation at the American Society of Nephrology (ASN) 2024 Annual Meeting Kidney Week

New minor risk - Share price stability

First half 2024 earnings released

ABIONYX Pharma Completes Pre-IND Meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis

ABIONYX Pharma SA, Annual General Meeting, Jun 27, 2024

ABIONYX Pharma SA to Report Q2, 2024 Results on Aug 22, 2024

New minor risk - Revenue size

Full year 2023 earnings released

ABIONYX Pharma SA to Report Q2, 2024 Results on Sep 26, 2024

ABIONYX Pharma SA Acknowledges the Clinical Results of the Phase 3 Aegis-Ii Study Evaluating the Efficacy and Safety of Csl Behring’S Human-Plasma-Derived Apoa-I, CSL112

ABIONYX Pharma Appoints Rob Scott as Chief Medical Officer and Head of R&D

ABIONYX Pharma Presents Preclinical Results for CER-001 in Brain Fog, At the 1st International Scientific Congress on Brain-Kidney Interaction in Naples on November 23-24, 2023

ABIONYX Pharma Announces New Positive Results in a Uveitis Model for the Strategic Development of the First Class of Biomedicines in Ophthalmology Based on its Recombinant apoA-I

Abionyx Pharma Racers Study Data in Sepsis Presented At the American Society of Nephrology (Asn) 2023 Annual Meeting "Kidney Week"

ABIONYX Pharma RACERS Study in Sepsis Selected for Late-Breaking Clinical Results Poster Presentation at the American Society of Nephrology 2023 Annual Meeting " Kidney Week"

First half 2023 earnings released

ABIONYX Pharma Successfully Manufactures a Second Batch of Recombinant Human ApoA-I CER-001 Using a New, Innovative and Robust Industrial Bioprocess

New major risk - Revenue and earnings growth

ABIONYX Pharma Announces New Compassionate Access Authorization (CAA) for CER-001 in the Rare Disease LCAT Deficiency or Norum Disease in Europe

ABIONYX Pharma Announces New Compassionate Access Authorization (CAA) for CER-001 in the Rare Disease LCAT Deficiency or Norum Disease in Europe

ABIONYX Pharma SA, Annual General Meeting, Jun 28, 2023

ABIONYX Pharma SA to Report Q2, 2023 Results on Aug 17, 2023

ABIONYX Pharma Announces Successful Manufacturing of the First Batch of CER-001 with Recombinant Human ApoA-I Using aNew Innovative and Robust Industrial Bioprocess

Full year 2022 earnings released

ABIONYX Pharma Reports Positive Results from Phase 2A Pilot Clinical Trial

ABIONYX Pharma SA to Report Fiscal Year 2022 Results on Apr 27, 2023

Insufficient new directors

Insufficient new directors

ABIONYX Pharma SA Announces Final Patient Enrollment in Phase 2a Clinical Trial with CER-001, Bio-HDL for the Treatment of Patients with Sepsis at High Risk of Developing Acute Kidney Injury

Insufficient new directors

First half 2022 earnings released

ABIONYX Pharma Reports Positive Interim Results from Phase 2A Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients At High Risk of Developing Acute Kidney Injury

ABIONYX Pharma Receives FDA Orphan Drug Designation (ODD) for CER-001 for the Treatment of LCAT Deficiency Presenting as Kidney Dysfunction and/or Ophthalmologic Disease

ABIONYX Pharma SA to Report First Half, 2022 Results on Sep 29, 2022

ABIONYX Pharma Announces That the French Drug Safety Agency Has Granted a Compassionate Access Authorization for the bio-HDL (CER-001) in COVID-19 Disease

ABIONYX Announces First Patient Enrolled in Phase 2a Clinical Study With CER-001, the Bio-HDL for the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day low: €0.83

ABIONYX Announces Positive Clinical Results From CER-001 in an Ultrarare Kidney Disease Published in the Annals of Internal Medicine

ABIONYX Pharma SA to Report First Half, 2021 Results on Sep 09, 2021

New 90-day high: €1.04

ABIONYX Pharma SA Initiates a Phase 2a Clinical Trial With CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury

ABIONYX Pharma Announces Publication of Pre-Clinical Data in the Journal Metabolism Demonstrating CER-001 Improves Lipid Profile and Kidney Function for an Ultra-Rare Kidney Disease

New 90-day high: €1.04

ABIONYX Pharma Announces the Observation of Positive Therapeutic Signals in Temporary Authorizations for Use (ATUn) in France and Italy for an Ultra-Rare Kidney Disease

New 90-day low: €0.71

ABIONYX Pharma SA announced that it expects to receive €1.859997 million in funding from Domundi SC and other investors

New 90-day low - €0.74

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines